Multi-omics Model for Pancreatic Cancer Screening Using cfDNA

RecruitingOBSERVATIONAL
Enrollment

480

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

December 30, 2025

Conditions
Pancreatic Cancer
Interventions
DIAGNOSTIC_TEST

A noninvasive cfDNA multi-omics assay

Peripheral venous blood samples will be collected from pancreatic cancer patients, individuals with precancerous lesions, and healthy controls. Subsequently, cfDNA will be extracted and subjected to low-pass whole genome sequencing (LP-WGS) and hybrid capture-based targeted methylation sequencing (TMS).

Trial Locations (1)

200032

RECRUITING

Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai

All Listed Sponsors
collaborator

Nanjing Simcere Medical Laboratory Science Co., Ltd.

UNKNOWN

lead

Fudan University

OTHER